Condensed Consolidated Statements of Operations - Unaudited - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 0	$ 2,000
Operating expenses:
Research and development	3,942	3,133
General and administrative	3,485	5,348
Total operating expenses	7,427	8,481
Operating loss	(7,427)	(6,481)
Other income (expense), net	1,791	(3,234)
Other (expense) income – related party	(238)	492
Interest income	100	0
Interest expense	0	(1)
Loss before income taxes and noncontrolling interest	(5,774)	(9,224)
Income tax provision	0	200
Net loss before noncontrolling interest	(5,774)	(9,424)
Less: net loss attributable to noncontrolling interest	(1,275)	(2,417)
Net loss attributable to vTv Therapeutics Inc.	(4,499)	(7,007)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$ (4,499)	$ (7,007)
Class A Common Stock
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share)	$ (0.06)	$ (0.10)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share)	$ (0.06)	$ (0.10)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)	81,483,600	66,942,777
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)	81,483,600	66,942,777